SCHEMBL2693448

SCHEMBL2693448

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(C(=O)CN4CCN(CC)CC4)ccc3OCC)nc12

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 19/20 0.85
PDE6C P51160 3/20 0.85
HDAC1 Q13547 10/20 0.65
HDAC6 Q9UBN7 10/20 0.65
HDAC2 Q92769 6/20 0.65
HDAC3 O15379 1/20 0.64
NCOR2 Q9Y618 1/20 0.64
PDE3B Q13370 3/20 0.63
PDE3A Q14432 3/20 0.63
KMT2A Q03164 2/20 0.62
PDE1A P54750 2/20 0.62
PDE1B Q01064 2/20 0.62
PDE1C Q14123 2/20 0.62
MEN1 O00255 1/20 0.62
ALDH1A1 P00352 1/20 0.62
HPGD P15428 1/20 0.62
PDE2A O00408 1/20 0.61
ABCC4 O15439 1/20 0.61
ABCC5 O15440 1/20 0.61
PDE6D O43924 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357402 1.00 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL30199753 0.95 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL25013469 0.95 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL18069561 0.94 PDE5A (0.77) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL28482244 0.94 PDE5A (0.83) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL7964961 0.94 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL28417929 0.93 PDE5A (0.82) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL7920627 0.93 PDE5A (0.82) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL7965731 0.93 PDE5A (0.84) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL147337 0.92 PDE5A (1.00) PDE5APDE6CHDAC1HDAC6HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111732593-A Piperazine oxide derivative and composition, preparation method and application thereof 黄泳华 2020-10-02 CN claimed
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US disclosed
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US disclosed
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions TECHFIELDS PHARMA CO., LTD. (CN) 2024-01-02 US disclosed
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions TECHFIELDS PHARMA CO., LTD. (CN) 2024-01-02 US disclosed
US-20230372351-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) 2023-11-23 US disclosed
US-11813256-B2 High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions PREMIER RESEARCH INTERNATIONAL, LLC 2023-11-14 US disclosed
US-11813256-B2 High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions PREMIER RESEARCH INTERNATIONAL, LLC 2023-11-14 US disclosed
US-11684624-B2 Treatment of erectile dysfunction and other indications STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) 2023-06-27 US disclosed
US-11684624-B2 Treatment of erectile dysfunction and other indications STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) 2023-06-27 US disclosed
US-20150174157-A1 INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY KAOHSIUNG MEDICAL UNIVERSITY (TW) 2015-06-25 US disclosed
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS PREMIER RESEARCH INTERNATIONAL, LLC 2015-03-12 US disclosed
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS PREMIER RESEARCH INTERNATIONAL, LLC 2015-03-12 US disclosed
US-20140086980-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) 2014-03-27 US disclosed
US-20140086980-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) 2014-03-27 US disclosed
US-20140051707-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) 2014-02-20 US disclosed
US-20140051707-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) 2014-02-20 US disclosed
US-8497370-B2 Processes for preparing amine salts of sildenafil-analogues and use thereof KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-07-30 US disclosed
US-8497370-B2 Processes for preparing amine salts of sildenafil-analogues and use thereof KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-07-30 US disclosed
US-20120108604-A1 PROCESSES FOR PREPARING AMINE SALTS OF SILDENAFIL-ANALOGUES AND USE THEREOF KAOHSIUNG MEDICAL UNIVERSITY (TW) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684624-B2 Treatment of erectile dysfunction and other indications PDE5A, PDE3A, PDE12 PDE5A 1/4885PDE6C 21/4885HDAC1 2431/4885
US-20140086980-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS PDE5A, PDE3A, PDE12 PDE5A 1/4885PDE6C 21/4885HDAC1 2431/4885
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH PDE5A 172/4885PDE6C 752/4885HDAC1 1829/4885
US-11813256-B2 High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions CPA3, PAH, HCAR2 PDE5A 469/4885PDE6C 1902/4885HDAC1 2739/4885
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH PDE5A 172/4885PDE6C 752/4885HDAC1 1829/4885
US-20140051707-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS PDE5A, PDE3A, PDE12 PDE5A 1/4885PDE6C 21/4885HDAC1 2431/4885
US-20230372351-A1 TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS PDE5A, PDE3A, PDE12 PDE5A 1/4885PDE6C 21/4885HDAC1 2431/4885
US-20120108604-A1 PROCESSES FOR PREPARING AMINE SALTS OF SILDENAFIL-ANALOGUES AND USE THEREOF PDE3A, PDE5A, PDE3B PDE5A 2/4885PDE6C 46/4885HDAC1 795/4885
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions HRH4, HCAR2, PAH PDE5A 172/4885PDE6C 752/4885HDAC1 1829/4885
US-20150174157-A1 INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY NOS2, NOS3, NOS1 PDE5A 27/4885PDE6C 533/4885HDAC1 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.